The business, which accounted for 26.5 percent of net sales in fiscal 2017, markets specialty generic drugs that include a variety of opioid-based products.
Mallinckrodt plans to spin off specialty generics business
Published in Industry News
More from Industry NewsMore posts in Industry News »
- Aurobindo, Unichem recall products in US market
- After recommending booster dose for 40+, INSACOG says more experiments needed
- Omicron scare: Experts advise booster doses for health workers
- BioNTech CEO confident of quickly adapting vaccine for Omicron
- Double vaccinate against Covid first, experts say amid calls for booster shots